lifestyle.longislandreport.org

Author: NOVO NORDISK INC.

Novo Nordisk’s Wegovy® HD available now nationwide

April 7, 2026
Wegovy® pill demonstrated greater weight loss than orforglipron and lower odds of stopping medication due to side effects in a new indirect comparison to be presented at Obesity Medicine Association 2026

April 2, 2026
Wegovy® pill demonstrated greater weight loss than orforglipron and lower odds of stopping medication due to side effects in a new indirect comparison to be presented at Obesity Medicine Association 2026

April 2, 2026
FDA approves Novo Nordisk’s new Wegovy® HD injection, delivering the highest weight loss to date for a Wegovy® injection, adding to its already expansive clinical profile

March 19, 2026
Novo Nordisk announces significant reduction in US list price for Wegovy®, Ozempic®, and Rybelsus® (semaglutide medicines), building on continued efforts to expand access

February 24, 2026
Novo Nordisk takes the field at the big game, putting Wegovy® pill in consumers’ hands

February 11, 2026
Novo Nordisk’s Wegovy® pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America

January 8, 2026
Novo Nordisk unveils the inaugural State of Weight and Health Report™, offering new insights that shed light on America’s obesity epidemic

January 6, 2026
FDA approves Novo Nordisk’s Wegovy® pill, the first and only oral GLP-1 for weight loss in adults

December 22, 2025
Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management

December 20, 2025